Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials

Angélique Vienot, Dewi Vernerey, Adeline Bouard, Elodie Klajer, Stefano Kim, Christophe Tournigand, Christophe Louvet, Thierry André, Benoît Rousseau, Mylène Wespiser, Laurie Spehner, Ying A. Wang, Anke Weispfenning, Emmanuelle Dochy, Christophe Borg

Open source

DOI: 10.1158/2767-9764.crc-24-0246
Published: 2025-02-01
Container: Cancer Research Communications
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-24-0246,
  title = {Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A
                    <i>Post Hoc</i>
                    Biomarker Analysis of the TEXCAN and CORRECT Trials},
  author = {Angélique Vienot and Dewi Vernerey and Adeline Bouard and Elodie Klajer and Stefano Kim and Christophe Tournigand and Christophe Louvet and Thierry André and Benoît Rousseau and Mylène Wespiser and Laurie Spehner and Ying A. Wang and Anke Weispfenning and Emmanuelle Dochy and Christophe Borg},
  year = {2025},
  journal = {Cancer Research Communications},
  doi = {10.1158/2767-9764.crc-24-0246},
  url = {https://doi.org/10.1158/2767-9764.crc-24-0246}
}

RIS

TY  - JOUR
TI  - Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A
                    <i>Post Hoc</i>
                    Biomarker Analysis of the TEXCAN and CORRECT Trials
AU  - Angélique Vienot
AU  - Dewi Vernerey
AU  - Adeline Bouard
AU  - Elodie Klajer
AU  - Stefano Kim
AU  - Christophe Tournigand
AU  - Christophe Louvet
AU  - Thierry André
AU  - Benoît Rousseau
AU  - Mylène Wespiser
AU  - Laurie Spehner
AU  - Ying A. Wang
AU  - Anke Weispfenning
AU  - Emmanuelle Dochy
AU  - Christophe Borg
PY  - 2025
JO  - Cancer Research Communications
DO  - 10.1158/2767-9764.crc-24-0246
UR  - https://doi.org/10.1158/2767-9764.crc-24-0246
ER  -

APA

Vienot, A., Vernerey, D., Bouard, A., Klajer, E., Kim, S., Tournigand, C., Louvet, C., André, T., Rousseau, B., Wespiser, M., Spehner, L., Wang, Y. A., Weispfenning, A., Dochy, E., & Borg, C. (2025). Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A <i>Post Hoc</i> Biomarker Analysis of the TEXCAN and CORRECT Trials. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-24-0246

Source records

crossref · retrieved 2026-09-26T15:44:59.362Z